Compare Neurocrine Biosciences Inc (NBIX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Waste Management, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $142.9 (market cap $14.36B), while Waste Management, Inc. trades at $208.12 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 5.8× Neurocrine Biosciences Inc's market cap, and Waste Management, Inc. pays a 1.8% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Waste Management, Inc. for 130 Days on average.
| NBIX | WM | |
|---|---|---|
Market Cap | $14.36B | $83.98B |
Volume | 1,237,180 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $185.50 | $246.51 |
52-Week Low | $123.10 | $196.77 |
Typical Hold Time | 23 Days | 130 Days |
Enterprise Value | $14.37B | $106.78B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Waste Management (WM) trades at $207.71, down 0.59% on the day, with a bullish technical signal despite bearish moving averages. The company reported revenue of $25.20 billion in 2025, with net income of $2.71 billion and a net margin of 10.74%. Recent earnings show mixed results, with a miss in Q4 2025 but beats in Q1 and Q2 2026. Analyst consensus is strongly positive with 54.29% buy ratings and no sell recommendations.
WM's outlook remains favorable due to steady revenue growth, strong cash flow, and a resilient business model. Key risks include elevated debt levels and competitive pressures. The stock offers a reliable dividend, with the next payment of $0.95 scheduled for September 25, 2026. Investors should weigh solid fundamentals against debt concerns for long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
